Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125900551 | 12590055 | 1 | I | 20160526 | 20160713 | 20160725 | 20160725 | EXP | FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059110 | BRISTOL MYERS SQUIBB | 74.92 | YR | M | Y | 0.00000 | 20160725 | CN | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125900551 | 12590055 | 1 | PS | COUMADINE | WARFARIN SODIUM | 1 | Oral | 1 TAB, BID | 398 | DF | 9218 | 1 | DF | TABLET | BID | ||||
| 125900551 | 12590055 | 2 | I | MODOPAR | BENSERAZIDE HYDROCHLORIDELEVODOPA | 1 | Oral | 1 DF, QD | 199 | DF | 0 | 1 | DF | CAPSULE | QD | ||||
| 125900551 | 12590055 | 3 | C | LOGIMAX | FELODIPINEMETOPROLOL SUCCINATE | 1 | Oral | 1 DF, QD | 199 | DF | 0 | 1 | DF | FILM-COATED TABLET | QD | ||||
| 125900551 | 12590055 | 4 | C | DIAMICRON | GLICLAZIDE | 1 | Oral | 3 TAB, QD | 597 | DF | 0 | 3 | DF | MODIFIED-RELEASE TABLET | QD | ||||
| 125900551 | 12590055 | 5 | C | ONGLYZA | SAXAGLIPTIN HYDROCHLORIDE | 1 | Oral | 1 DF, QD | 199 | DF | 0 | 1 | DF | FILM-COATED TABLET | QD | ||||
| 125900551 | 12590055 | 6 | C | XATRAL | ALFUZOSIN | 1 | Oral | 1 DF, QD | 199 | DF | 0 | 1 | DF | TABLET | QD | ||||
| 125900551 | 12590055 | 7 | C | AZILECT | RASAGILINE MESYLATE | 1 | Oral | 1 DF, QD | 199 | DF | 0 | 1 | DF | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125900551 | 12590055 | 1 | Product used for unknown indication |
| 125900551 | 12590055 | 2 | Parkinson's disease |
| 125900551 | 12590055 | 3 | Hypertension |
| 125900551 | 12590055 | 4 | Product used for unknown indication |
| 125900551 | 12590055 | 5 | Type 2 diabetes mellitus |
| 125900551 | 12590055 | 6 | Benign prostatic hyperplasia |
| 125900551 | 12590055 | 7 | Parkinson's disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125900551 | 12590055 | OT |
| 125900551 | 12590055 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125900551 | 12590055 | Drug interaction | |
| 125900551 | 12590055 | Epistaxis | |
| 125900551 | 12590055 | Fall | |
| 125900551 | 12590055 | Head injury | |
| 125900551 | 12590055 | Skull fracture | |
| 125900551 | 12590055 | Subdural haematoma |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125900551 | 12590055 | 1 | 20151110 | 20160526 | 0 | |
| 125900551 | 12590055 | 2 | 20151110 | 20160526 | 0 | |
| 125900551 | 12590055 | 3 | 20151110 | 20160526 | 0 | |
| 125900551 | 12590055 | 4 | 20151110 | 20160526 | 0 | |
| 125900551 | 12590055 | 5 | 20151110 | 20160526 | 0 | |
| 125900551 | 12590055 | 6 | 20151110 | 20160526 | 0 | |
| 125900551 | 12590055 | 7 | 20151110 | 20160526 | 0 |